The Efficacy of Dose-Dense Neoadjuvant Chemotherapy for Patients with Non-Metastatic Breast Cancer and Clinicopathological Factors Affecting Pathological Response

Abstract

Many therapeutic approaches have emerged to improve pathological complete response, which has a prognostic value for breast cancer patients. The most important approach was dose-dense neoadjuvant chemotherapy and we aim to study its efficacy in this study.

The study included 115 patients who attended the Chemotherapy and Radiotherapy Center in Latakia University Hospital between 2021 and 2024 with non metastatic breast cancer eligible for neoadjuvant therapy. All patients received dose-dense neoadjuvant chemotherapy with G-SCF then they underwent surgery with total or conservative mastectomy with axillary lymph node dissection.

The rate of patients achieving pathological complete response (pCR) was 45.21% , the rate of non-pCR  was  54.75% .The highest response rate was in HR- , HER2+ patients, with a pathological complete response of 77.7%. A better response was observed in patients who did not have lymphadenopathy at diagnosis and who had grade III tumors.

Dose-dense neoadjuvant chemotherapy is an important treatment approach for breast cancer, especially for TNBC, HER2+ patients.